Changing U.S. Agents or Import Partners Without Losing Control

Changing a U.S. Agent or import partner involves far more than updating contact information. Careful planning, record transfers, and role coordination help maintain regulatory compliance and operational continuity during a transition.

A Transition Is an Operational Event

Changing a U.S. Agent, Initial Importer, Importer of Record, or distribution partner is not simply a matter of replacing one company name with another.

Regulatory access, import instructions, complaint records, customer information, and agency communications may be distributed across several systems and organizations.

A poorly controlled transition can leave an obsolete U.S. Agent in an FDA registration, cause a customs broker to transmit outdated importer data, or allow complaints and official correspondence to remain with a provider that is no longer responsible.

Map Every Role Before Giving Notice

Before terminating an arrangement, the foreign manufacturer should identify every function the outgoing party actually performs.

These functions may include U.S. Agent, Official Correspondent, Initial Importer, Importer of Record, customs contact, complaint intake, Medical Device Reporting triage, recall communications, warehousing, and distribution.

One organization may perform several of these functions, but each requires its own successor, effective date, responsible owner, and handover method.

Where practical, the transition plan should provide a defined overlap period. The incoming party needs sufficient information and authority to become operational before the outgoing party’s access, personnel, email addresses, or systems are withdrawn.

Update Registrations and Import Data Deliberately

A U.S. Agent change should be entered in the foreign establishment’s FDA registration and completed through the applicable agent-confirmation process.

The manufacturer should also review owner/operator access, Official Correspondent details, device listings, and identified U.S. importers rather than assuming that changing the agent updates everything else.

Customs brokers, freight forwarders, manufacturers, and shipping teams must receive controlled entry instructions showing the correct parties, identifiers, product data, and regulatory references.

Open shipments, pending entries, returns, and historical entry records should be specifically addressed so the transition does not create inconsistent data or prevent later retrieval.

Preserve Complaint and Agency Continuity

The handover should include open and closed complaint files, reportability assessments, submitted reports, investigation status, corrections and removals, recall records, customer traceability, returns, and unresolved quality issues.

Transfer does not remove any applicable retention obligations, so both access and custody must be documented.

The parties should also inventory all open FDA and other agency matters, including import holds, document requests, inspection correspondence, registration notices, and recall communications.

Contractual forwarding and cooperation obligations are useful, but the manufacturer should retain its own records, account control, escalation contacts, and operational visibility throughout the relationship.

Maintain Operational Continuity Through the Change

MDD Options can help manufacturers plan and execute transitions involving U.S. Agent, Initial Importer, Importer of Record, complaint-management, recall, import, and distribution functions.

Its Hybrid operating model can establish replacement roles, coordinate regulatory and broker updates, transfer controlled records, preserve channel visibility, and maintain operational continuity while the manufacturer changes representatives or commercial partners.